Clinical Trial Update: Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19 (ANA-COVID-GEAS) [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for anakinra in cytokine storm syndrome related to COVID-19 (ANA-COVID-GEAS) completed phase 2 and phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COVID-19 Pneumonia

Drugs mentioned

• Anakinra (anakinra)

Snippet

Sponsor: Fundacion Miguel Servet | Conditions: COVID-19 Pnemonia | Phase 2, Phase 3 | Status: COMPLETED